Global Bacteriophage Therapy Market Trends, Investment Opportunities And Growth Forecast 2026-2035
The global bacteriophage therapy market is projected to expand from USD 66.5 million in 2026 to USD 266.8 million by 2035, representing a compound annual growth rate of approximately 16.7% during the forecast period. Market expansion is being driven by the escalating burden of antimicrobial resistance, advances in phage engineering, increasing clinical activity and growing public- and private-sector investment.
Bacteriophage Therapy Market Growth and Trends
Antimicrobial resistance continues to increase demand for anti-infective therapies capable of treating persistent and multidrug-resistant bacterial infections. Global estimates associate antimicrobial resistance with approximately 1.27 million deaths annually, highlighting the limitations of existing antibiotics and the need for precision antimicrobial strategies.
Bacteriophage therapeutics offer pathogen-specific activity, microbiome preservation, biofilm disruption and potential effectiveness against antibiotic-resistant bacteria. These attributes are supporting their evaluation in recurrent infections, chronic conditions and difficult-to-treat bacterial diseases. The market is also transitioning from academic research and compassionate-use programs toward controlled clinical trials and commercially scalable development platforms.
Biotechnology companies are advancing engineered bacteriophages, pathogen-specific phage cocktails and combination therapies intended to improve clinical efficacy, expand bacterial coverage and reduce resistance development. Progress in synthetic biology, genome engineering, bioinformatics and artificial intelligence-enabled phage discovery is further accelerating candidate identification and supporting personalized treatment development.
Key Market Growth Drivers
- Increasing prevalence of multidrug-resistant bacterial infections and antibiotic treatment failures. Limited availability of novel antibacterial drugs for complex and recurrent infections. Growing clinical interest in targeted treatments that preserve beneficial microbial populations. Advances in synthetic biology, genome engineering and optimized phage-cocktail development. Expanding government funding, non-dilutive financing and private investment. Strategic collaborations among biotechnology companies, hospitals, academic institutions and public agencies.
Funding and partnership activity continue to strengthen the bacteriophage therapy market. BiomX has received approximately USD 40 million in non-dilutive funding from the US Defense Health Agency and the Department of the Navy through the Medical Technology Enterprise Consortium to advance its Staphylococcus aureus phage therapy programs. The company also raised approximately USD 12 million to support its BX004 Phase IIb program for chronic Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Industry consolidation is expanding intellectual property portfolios, phage libraries and personalized therapy capabilities. BiomX's acquisition of Adaptive Phage Therapeutics illustrates this trend, while the initiation of Phase IIb patient dosing for BX004 reflects broader progress from early access programs toward structured clinical development.
Market Challenges
The absence of globally harmonized regulatory pathways remains a significant barrier. Existing pharmaceutical approval frameworks do not always accommodate adaptable, pathogen-specific or customized phage products. Regulatory uncertainty can increase development risk, extend review timelines and create additional compliance requirements.
Commercial-scale manufacturing also presents challenges related to product purity, potency, biological variability and batch consistency. Personalized phage cocktails require flexible production infrastructure, validated purification technologies, rigorous quality controls and rapid turnaround times. Addressing these requirements will be essential to achieving reliable clinical supply and broader commercialization.
Bacteriophage Therapy Market Segmentation
The report evaluates the global bacteriophage therapy market by target indication, route of administration, targeted bacteria and geographical region.
- Target indications: bacterial dysentery, enteric infections, gastrointestinal infections, multiple infections, prosthetic joint infections and urinary tract infections. Routes of administration: intravenous, oral, rectal and topical. Targeted bacteria: Escherichia coli, Pseudomonas aeruginosa, Salmonella, Staphylococcus aureus, Streptococcus and other bacterial strains. Regions: North America, Europe, Asia-Pacific and the rest of the world.
Key Segment Insights
Urinary tract infections currently account for the largest share of the bacteriophage therapy market, supported by the high incidence of recurrent and multidrug-resistant infections, particularly those associated with Escherichia coli. The prosthetic joint infection segment is expected to register the highest growth rate through 2035 as orthopedic implant procedures increase and demand rises for treatments capable of addressing bacterial biofilms.
By route of administration, oral bacteriophage therapy holds the largest market share. Its position is supported by progress in enteric-coated and microencapsulated formulations designed to improve phage stability in the gastrointestinal environment. Topical administration is projected to record the fastest growth, driven by rising rates of chronic wound infections, diabetic foot ulcers and surgical-site infections.
North America is expected to maintain the largest share of global bacteriophage therapy market revenue through 2035. Regional leadership is supported by an established clinical research ecosystem, strong financing activity and the presence of specialized developers. Asia-Pacific is forecast to be the fastest-growing regional market due to its increasing antimicrobial resistance burden, expanding biotechnology capabilities and greater government focus on infectious disease management across China, India, Japan, South Korea and Australia.
Companies Active in the Bacteriophage Therapy Market
- Adaptive Phage Therapeutics ContraFect Eliava BioPreparations Micreos NPO Microgen Phagelux AgriHealth Pherecydes Pharma
The competitive assessment examines company profiles, product pipelines, clinical programs, financial activity, patents, partnerships and recent developments. Industry insights are informed by interviews with executives, scientists, researchers, consultants and production specialists across the United States, France, Israel, Greece, Switzerland and Portugal.
Research Coverage
The bacteriophage therapy market report includes market sizing and revenue forecasts, developer benchmarking, drug and company profiles, clinical trial analysis, patent evaluation, scientific publication benchmarking, academic grant analysis, funding activity and partnership trends. It also assesses market drivers, restraints, commercialization opportunities and competitive positioning across major geographical regions.
The research addresses leading companies, dominant indications, targeted bacterial segments, regional growth patterns, clinical trial activity, patent portfolios, financing trends and strategic collaborations. It also evaluates how the global market opportunity may be distributed across indications, administration routes, bacterial targets and regions through 2035.
Business Value of the Report
Developed for distributors, channel partners, investors and business development teams, the report provides detailed revenue projections and actionable intelligence for evaluating market-entry and expansion strategies. Stakeholders can use the findings to assess customer demand, compare emerging opportunities, identify potential collaborators and strengthen strategic decision-making.
Additional deliverables include presentation materials, Excel data packs for analytical modules, an insights package, report customization, a research-team walkthrough and a complimentary update for qualifying reports more than six months old.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment